NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
- State
- Completed
- Phase
- Phase 3
- People
- 2,749 taking part
- Started
- 3 Apr 2023
- Primary completion
- 16 Mar 2026
- Arms
- Orforglipron
- Results
- None posted
- 3 Apr 2023: Trial started
- 7 Apr 2023: Trial registered
- 16 Mar 2026: Trial completed